Elanco’s Parvovirus Antibody Treatment Saves Thousands of Puppies in First Year
Elanco Animal Health has released the first real-world data showcasing the effectiveness of its Canine Parvovirus Monoclonal Antibody (CPMA), the first USDA Conditionally Approved targeted treatment for canine parvovirus. Each year, over 330,000 puppies are affected by this deadly virus, which has a mortality rate of up to 91% without supportive care. The data collected during CPMA’s first year on the market highlights significant improvements in puppy survival rates, enhanced clinic efficiency, and high levels of satisfaction among veterinary staff, demonstrating that CPMA is transforming parvovirus treatment protocols.
“Elanco embarked on a mission to save 1 million puppies from parvovirus by 2030, and I’m proud to say that in just the first year, we’ve saved thousands of puppies—including pets like Cookie, Mono, and Luna,” said Bobby Modi, Executive Vice President of U.S. Pet Health at Elanco.
Key findings from the real-world data include:
- 93% survival rate for puppies treated with CPMA.
- Reduced hospital stays, with parvo patients spending an average of 1.87 fewer days in the hospital.
- 92% of veterinarians reported that CPMA reduced overall clinic stress.
- 90% satisfaction rate among clinics using CPMA in their treatment protocols.
- 83% of users recommended CPMA to other veterinary professionals.
“Our real-world data underscores the impact CPMA is having on puppies and clinic staff,” said Dr. Jennifer Miller, a technical veterinarian at Elanco. “We understand the immense stress veterinarians face when treating parvovirus, and we’re thrilled to provide a solution that truly improves both patient outcomes and clinic operations.”
As part of its “Defend Puppies. Defeat Parvo” initiative, Elanco has also launched the Parvo Defenders Task Force and an innovative online tracking tool called ParvoTrack, which has logged 900 reported parvo cases from veterinarians and pet owners. Over 7,000 pet owners have signed up for parvo alerts through ParvoTrack, enabling dog owners and veterinary professionals to receive real-time notifications about outbreaks in their area. To join the fight against parvovirus and sign up for alerts, visit DefeatParvo.com.
“As a member of the Parvo Defenders Task Force, I’ve seen firsthand the transformative impact of CPMA,” said Dr. Fred Metzger from VCA Metzger Animal Hospital. “The treatment has not only improved survival rates but has also significantly reduced stress and workload in our clinic, allowing us to focus on other animals in need. I strongly recommend CPMA to my fellow veterinarians.”
About Elanco
Elanco Animal Health Incorporated is a global leader in animal health, dedicated to developing innovative products for farm animals and pets. With nearly 70 years of expertise, Elanco is committed to enhancing animal health, supporting farmers, pet owners, and veterinarians, and contributing to local and global communities. Guided by its vision of “Food and Companionship Enriching Life,” Elanco focuses on sustainability to benefit animals, people, the planet, and the organization itself.
